General RPROFILD project information

Last updated: 2023-07-18 10:07

Project name

Real-world data collection on the diagnosis, disease course and outcomes for patients suffering from PROgressive Fibrosing Interstitial Lung Disease (RPROFILD)

Project abbreviation

RPROFILD

Project code

HDBP0244

Primary organization that oversees implementation of project

  • Boehringer Ingelheim Comm.

Partner organization participating in project

  • Not applicable

Organization that commissioned this project

  • National Institute for Health and Disability Insurance (RIZIV-INAMI)

Organization providing monetary or material support

  • Boehringer Ingelheim Comm.

Brief project description

Ofev® is reimbursed in Belgium in two indications: Idiopathic Pulmonary Fibrosis (IPF, paragraph 7780000) and non-IPF progressive fibrosing interstitial lung disease (non-IPF PF-ILD, paragraph 11530000). Progressive fibrosing interstitial lung disease (PF-ILD) is the umbrella terminology used for IPF + non-IPF PF-ILD. PF-ILDs are characterized by a self-sustaining progressive fibrosis of the lung, worsening respiratory symptoms, declining lung function, worsening quality of life, and early death in absence of active treatment. Ofev® is an efficacious and safe antifibrotic treatment that delays the lung function decline (measured as forced vital capacity (FVC) decline) of affected patients.

Regulatory framework of this project

Consult the regulatory framework information published on the fair.healthdata.be pages.